Skip main navigation

Military Health System

Clear Your Browser Cache

This website has recently undergone changes. Users finding unexpected concerns may care to clear their browser's cache to ensure a seamless experience.

2023-2024 Mid-Season Influenza Vaccine Effectiveness Against Laboratory-Confirmed Ambulatory Influenza: DOD TRICARE Beneficiaries

Image of 48088663. This study presents the results of a vaccine effectiveness estimate against ambulatory influenza infections among Department of Defense TRICARE beneficiaries.

The DOD Global Respiratory Pathogen Surveillance Program1 used a matched case-test negative control study design to determine VE estimates against ambulatory influenza among DOD TRICARE beneficiaries. Specimens were collected from October 1, 2023 to February 17, 2024 among individuals with an influenza-like illness medical encounter, then analyzed either at the United States Air Force School of Aerospace Medicine or Landstuhl Regional Medical Center. An ILI encounter was defined as presenting with a fever (≥100.4°F) and cough, fever (≥100.4°F) and two or more additional symptoms (fatigue, body aches, sore throat, headache, sinus congestion, shortness of breath, chills, runny nose, loss of taste or smell, acute respiratory distress) or a physician-diagnosed ILI. The study excluded service members, who were evaluated separately by the Armed Forces Health Surveillance Division. 

Cases were individuals with a laboratory-confirmed positive influenza specimen, while controls were those with a specimen testing negative for influenza. An attempt was made to match each case to four controls by the month of specimen collection, but due to control availability, some analyses only had one case to three controls. Vaccination status was determined by utilizing the Aeromedical Services Information Management System or self-reporting through DODGRPSP questionnaires. Individuals were considered vaccinated if they received the vaccine at least 14 days prior to specimen collection, with exclusions for vaccines received within 14 days. Adjusted ORs and 95% CIs were calculated via multivariable logistic regression, adjusting for age group and geographic region. Adjusted VE estimates were computed as (1 - aOR) x 100. 

Click on the table to access a 508-compliant PDF version

The study identified 158 cases and 479 controls. Adjusted VE estimates for all DOD beneficiaries showed 35% effectiveness (CI: 4, 56) against overall influenza, 32% (CI: -8, 57) against overall influenza A, 40% (CI: -15, 69) against influenza A(H1N1)pdm09, 54% (CI: -31, 84) against influenza A(H3N2), and 67% (CI: 17, 87) against influenza B. For children, the adjusted VE estimate was 43% (CI: 0, 67) against overall influenza, while for adults it was 52% (CI: 11, 74) against overall influenza. 

VE estimates suggest statistically significant, low to moderate protection against overall influenza among all DOD TRICARE beneficiaries and adults, as well as against influenza B among all DOD TRICARE beneficiaries. VE estimates against overall influenza for children, overall influenza A for all DOD TRICARE beneficiaries, influenza A(H1N1)pdm09, and influenza A(H3N2) for all DOD TRICARE beneficiaries indicate low to moderate protection, but these results did not reach statistical significance. 

Reference

  1. Kwaah B, Gruner WE, DeMarcus L, et al. Surveillance trends for SARS-CoV-2 and other respiratory pathogens among US military health system beneficiaries, 27 September 2020–2 October 2021. MSMR. 2022;29(7):2-10.

You also may be interested in...

Article
Mar 1, 2024

Coverage of HIV Pre-Exposure Prophylaxis Within the Active Duty U.S. Military, 2023

This study provides the first estimate of HIV pre-exposure prophylaxis coverage in the U.S. military, defined as the proportion of the persons taking HIV PrEP out of the estimated number of persons who had indications for it, that is also comparable to U.S. civilian estimates. The population with indications for HIV PrEP was obtained from the ...

Article
Mar 1, 2024

Mid-Season Influenza Vaccine Effectiveness Estimates Among DOD Populations: A Composite of Data Presented at VRBPAC—the Vaccines and Related Biological Products Advisory Committee—2024 Meeting on Influenza Vaccine Strain Selection for the 2024-2025 Influenza Season

This is an introduction to a composite of three Surveillance Snapshots of Department of Defense data on mid-season influenza vaccine effectiveness that were presented at the 2024 VRBPAC meeting.

Article
Mar 1, 2024

Tobacco and Nicotine Use Among Active Component U.S. Military Service Members: A Comparison of 2018 Estimates from the Health Related Behaviors Survey and the Periodic Health Assessment

This study compared estimates of the prevalence of and risk factors for tobacco and nicotine use obtained from the 2018 Health Related Behaviors Survey and Periodic Health Assessment survey. The HRBS and the PHA are important Department of Defense sources of data on health behavior collected from U.S. military service members.

Report
Mar 1, 2024

MSMR Vol. 31 No. 3 - March 2024

.PDF | 1.34 MB

The March 2024 MSMR features a comparison of 2018 estimates from the HRBS and the PHA on tobacco and nicotine use among the U.S. military active component; followed by a report on coverage of HIV PrEP among active duty service members in 2023; supplemented by a Surveillance Snapshot of HIV PrEP prescriptions in 2023 in the active component; then a ...

Article
Jan 1, 2024

Ivermectin Prescription Fill Rates Among U.S. Military Members During the Coronavirus Disease 2019 (COVID-19) Pandemic

This report describes ivermectin prescription fill rates among U.S. active component service members over time during the early phases of the COVID-19 pandemic. Ivermectin prescription fill rates increased among active component service members early in the COVID-19 pandemic when misinformation about the effectiveness of ivermectin for prevention and ...

Skip subpage navigation
Refine your search
Last Updated: May 07, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery